



'In establishing PharmaQest, ITEK has created a sound organisational and business structure from which to commercialise our pharmaceutical products and generate returns for creators of intellectual property and the University'.

Prof Allan Evans

Director of the School of Pharmacy and Medical Sciences and
Director: Research and Development PharmaQest



itek

PHARMAQEST Pty Ltd

PharmaQest Pty Ltd is an Australian drug development company, established for the purpose of developing chemopreventive product(s) for non-melanoma skin cancer ('NMSC') applications.

Innovation

Cancer Council of SA figures show that in 2005 in South Australia, 8,456 new cases of cancer were diagnosed, 4,760 of these cases were among men and 3,696 were among women. Basal Cell Carcinomas (BCCs) are the most common form of skin cancer. Whilst usually not deadly, BCCs do cause significant skin problems and require surgery.

The School of Pharmacy and Medical Sciences at the University of South Australia has developed a novel skin cancer drug which could prevent this common form of skin cancer.

Opportunity

The treatment has considerable market potential for those with sun-damaged skin and others with a

predisposition to non-melanoma skin cancers. Since approximately 40% of all people develop skin cancer within their lifetime, with a 5 year recurrence rate of about 20-30%.

Commercial Achievements

PharmaQest was established by ITEK to commercialise the platform technology and other pharmaceutical products developed at the School of Pharmacy and Medical Sciences.

ITEK has secured a CEO with a track record in capital raising and commercialising biotechnology companies.

Under Ross Dobinson's leadership, PharmaQest has partnered with Italian Pharmaceutical company Sigma-Tau Pharmaceuticals Inc to design and manufacture the skin cancer drug for global markets.

success stories

